Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 4/20 | 0.72 |
| ▸ | PRKDC | P78527 | 1/20 | 0.72 |
| ▸ | ATM | Q13315 | 1/20 | 0.72 |
| ▸ | NPC1 | O15118 | 6/20 | 0.54 |
| ▸ | RAB9A | P51151 | 6/20 | 0.54 |
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | ILK | Q13418 | 5/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | APP | P05067 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | MMP9 | P14780 | 1/20 | 0.51 |
| ▸ | MMP8 | P22894 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.51 |
| ▸ | RELA | Q04206 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24681636 | 0.86 | ATR (0.59) | ATRPRKDCATMNPC1RAB9A | |
| SCHEMBL20433664 | 0.86 | ATR (0.69) | ATRPRKDCATMNPC1RAB9A | |
| SCHEMBL2482361 | 0.84 | ATR (1.00) | ATRPRKDCATMNPC1RAB9A | |
| SCHEMBL20433433 | 0.84 | ATR (0.69) | ATRPRKDCATMNPC1RAB9A | |
| SCHEMBL13138758 | 0.82 | PRKDC (0.57) | ATRPRKDCATMNPC1RAB9A | |
| SCHEMBL13346073 | 0.81 | PRKDC (0.56) | ATRPRKDCATMNPC1RAB9A | |
| SCHEMBL2386563 | 0.78 | ATR (0.54) | ATRPRKDCATMNPC1RAB9A | |
| SCHEMBL6701248 | 0.78 | ATR (0.66) | ATRPRKDC | |
| SCHEMBL32688927 | 0.78 | ATR (0.66) | ATRPRKDC | |
| SCHEMBL1128092 | 0.77 | NPC1 (0.57) | ATRPRKDCATMNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230030414-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED | 2023-02-02 | — | — | US | disclosed |
| EP-3354650-B1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMA (US) | 2022-02-16 | — | — | EP | disclosed |
| US-11179394-B2 | Method for treating cancer using a combination of Chk1 and ATR inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-11-23 | — | — | US | disclosed |
| US-11110086-B2 | Compounds useful as inhibitors of ATR kinase and combination therapies thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-09-07 | — | — | US | disclosed |
| US-10961232-B2 | Substituted pyrazines as ATR kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-03-30 | — | — | US | disclosed |
| US-20200222392-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE AND COMBINATION THERAPIES THEREOF | VERTEX PHARMACEUTICALS (EUROPE) LIMITED (GB) | 2020-07-16 | — | — | US | disclosed |
| US-10479784-B2 | Substituted pyrazin-2-amines as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-11-19 | — | — | US | disclosed |
| US-10478430-B2 | Compounds useful as inhibitors of ATR kinase and combination therapies thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-11-19 | — | — | US | disclosed |
| EP-3157566-B1 | METHOD FOR TREATING CANCER USING A COMBINATION OF CHK1 AND ATR INHIBITORS | VERTEX PHARMA (US) | 2019-05-01 | — | — | EP | disclosed |
| US-20190047995-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED | 2019-02-14 | — | — | US | disclosed |
| US-9701674-B2 | Substituted pyrazines as ATR kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-07-11 | — | — | US | disclosed |
| US-20160311809-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-10-27 | — | — | US | disclosed |
| US-9365557-B2 | Substituted pyrazin-2-amines as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-06-14 | — | — | US | disclosed |
| US-20160030424-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE AND COMBINATION THERAPIES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-02-04 | — | — | US | disclosed |
| US-20150359797-A1 | METHOD FOR TREATING CANCER USING A COMBINATION OF CHK1 AND ATR INHIBITORS | VERTEX PHARMACEUTICALS (EUROPE) LIMITED (GB) | 2015-12-17 | — | — | US | disclosed |
| US-20150051187-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED | 2015-02-19 | — | — | US | disclosed |
| US-20150031661-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-01-29 | — | — | US | disclosed |
| US-8841308-B2 | Pyrazin-2-amines useful as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-23 | — | — | US | disclosed |
| US-20140044802-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE AND COMBINATION THERAPIES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-02-13 | — | — | US | disclosed |
| US-20100222318-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200222392-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE AND COMBINATION THERAPIES THEREOF | ATR, CHEK1, CHEK2 | ATR 1/4885PRKDC 13/4885ATM 14/4885 |
| US-11110086-B2 | Compounds useful as inhibitors of ATR kinase and combination therapies thereof | ATR, CHEK1, CHEK2 | ATR 1/4885PRKDC 20/4885ATM 16/4885 |
| US-10961232-B2 | Substituted pyrazines as ATR kinase inhibitors | ATR, MAP3K5, CHEK1 | ATR 1/4885PRKDC 29/4885ATM 41/4885 |
| US-20100222318-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, CHEK1, MAP3K5 | ATR 1/4885PRKDC 23/4885ATM 39/4885 |
| US-11179394-B2 | Method for treating cancer using a combination of Chk1 and ATR inhibitors | CHEK1, CHEK2, ATR | ATR 3/4885PRKDC 73/4885ATM 7/4885 |
| US-20150031661-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, CHEK1, MAP3K5 | ATR 1/4885PRKDC 23/4885ATM 39/4885 |
| US-20190047995-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, CHEK1, MAP3K5 | ATR 1/4885PRKDC 23/4885ATM 39/4885 |
| US-20150359797-A1 | METHOD FOR TREATING CANCER USING A COMBINATION OF CHK1 AND ATR INHIBITORS | CHEK1, CHEK2, ATR | ATR 3/4885PRKDC 73/4885ATM 7/4885 |
| US-20230030414-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, CHEK1, MAP3K5 | ATR 1/4885PRKDC 23/4885ATM 39/4885 |
| US-10478430-B2 | Compounds useful as inhibitors of ATR kinase and combination therapies thereof | ATR, CHEK1, CHEK2 | ATR 1/4885PRKDC 20/4885ATM 16/4885 |
| US-20140044802-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE AND COMBINATION THERAPIES THEREOF | ATR, CHEK1, CHEK2 | ATR 1/4885PRKDC 20/4885ATM 16/4885 |
| US-20160030424-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE AND COMBINATION THERAPIES THEREOF | ATR, CHEK1, CHEK2 | ATR 1/4885PRKDC 20/4885ATM 16/4885 |
| US-10479784-B2 | Substituted pyrazin-2-amines as inhibitors of ATR kinase | ATR, CHEK2, CHEK1 | ATR 1/4885PRKDC 31/4885ATM 28/4885 |
| US-20160311809-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, CHEK1, MAP3K5 | ATR 1/4885PRKDC 23/4885ATM 39/4885 |
| US-20150051187-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, CHEK1, MAP3K5 | ATR 1/4885PRKDC 23/4885ATM 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.